Psychedelic Drugmaker Definium Surges on Depression Drug Success

Definium Therapeutics Inc. shares surged up to 60% on Monday, March 11, 2024, following the release of late-stage clinical trial data for its experimental treatment targeting major depressive disorders. The company reported "groundbreaking" results from the trial, which involved 200 participants across 15 sites in the United States and Canada. The trial met its primary endpoint, demonstrating a statistically significant reduction in depressive symptoms compared to a placebo group. Specifically, the treatment group showed a 45% greater improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS) after six weeks. Definium Therapeutics plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. The company also announced it has secured $75 million in Series C funding to support the upcoming regulatory submission and potential commercial launch. This positive outcome positions Definium Therapeutics as a significant contender in the emerging field of psychedelic-assisted therapies for mental health conditions.